CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb Spasticity

Inclusion Criteria:

1. The patient is able to comply with the protocol;

2. Male and female patients who are at least 18 years old;

3. The patient is supported by an identified caregiver (family member or other nonpaidadult

• if the patient has more than one caregiver, the main caregiver will beselected) who provides daily supervision or direct assistance to the carerecipient;

4. The patient has been diagnosed with ULS due to non-progressive acquired braininjuries (stroke, traumatic brain injury, surgical resection of non-progressivetumours, other) or due to non-progressive spinal cord injury with stability ofspasticity of the upper limbs;

5. The decision to treat the patient with AboBoNT-A by the care provider will be madeprior to, and independently from the decision to enrol the patient in theobservational study;

6. The patient is covered by a healthcare insurance;

7. The cognitive and health status of the patient is compatible with the participationto the study.

For Caregivers :

(8) The caregiver is able to comply with the protocol; (9) Male and female caregivers who are at least 18 years old; (10) The cognitive and health status of the caregiver is compatible with the participation to the study.

Exclusion Criteria:

1. Contraindication to BoNT-A treatment;

2. Previously treated with BoNT-A in upper limbs within the last 12 months;

3. Patients and if applicable Legally Authorized Representative (LAR) of patient undercuratorship or deprived of liberty who are opposed to their data collection

4. Caregivers who are opposed to their data collection;

5. Caregivers already included for another patient;

6. Current participation in any other interventional clinical study or haveparticipated within the 12 weeks prior to the inclusion visit;

7. Non-ambulatory patients except for those who have been hospitalized for the purposeof their BoNT-A injection (maximum length of stay as per clinical judgment of theinvestigator);

8. Vulnerable patients (i.e. pregnant and/or lactating women, children, patient undercuratorship or deprived of liberty).